We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
Eli Lilly has expanded a collaboration with ... The partnership will explore health and activity monitoring innovations combining Garmin wearables with ActiGraph‘s CentrePoint data analytics ...
A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge ... specialist Sidekick and pharma group Eli Lilly. The two companies say the ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...
Compounding pharmacies such as Hims & Hers Health producing their own versions of tirzepatide likely pressured demand for Eli Lilly's branded version in the second half of 2024. The Food and Drug ...
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,020.00. Akash Tewari’s rating is based ...
Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback